Tsumura & Co. (JP:4540)
:4540
Want to see JP:4540 full AI Analyst Report?
4540 Stock Chart & Stats
¥3599.00
¥9.00(0.19%)
At close: 4:00 PM EST
¥3599.00
¥9.00(0.19%)
Day’s Range― - ―
52-Week Range¥3,306.00 - ¥4,403.00
Previous CloseN/A
Volume145.30K
Average Volume (3M)448.06K
Market Cap
¥282.47B
Enterprise Value¥340.97B
Total Cash (Recent Filing)¥69.48B
Total Debt (Recent Filing)¥135.41B
Price to Earnings (P/E)7.1
Beta0.50
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.3%
Share Statistics
EPS (TTM)142.95
Shares Outstanding76,758,360
10 Day Avg. Volume373,220
30 Day Avg. Volume448,060
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)1.81
P/FCF Ratio52.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)356.89
Revenue Forecast (FY)¥213.25B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityTsumura's high gross and solid net margins reflect a profitable business model based on standardized Kampo formulations and in‑house manufacturing. Durable margins support reinvestment in quality control, product supply and targeted R&D, providing long‑term earnings stability versus low‑margin peers.
Multi-year Revenue GrowthSustained top‑line expansion over multiple years demonstrates durable demand for prescription Kampo medicines under Japan's reimbursement system. Consistent revenue growth supports scale advantages in manufacturing and distribution, reducing unit costs and underpinning predictable sales over the medium term.
Substantial Equity And Moderate LeverageA sizeable equity base and moderate leverage provide financial flexibility to fund manufacturing, quality control and product development. Even with increased debt versus FY2025, the capital structure still offers a cushion to absorb shocks and support long‑term operational commitments.
Bears Say
Weak Cash GenerationNegative trailing free cash flow indicates that reported earnings are not fully converting to cash, increasing dependency on external financing. Over 2–6 months this reduces flexibility for capex, working capital management and shareholder returns, and raises the risk of funding pressure if trends persist.
Rising Leverage Vs FY2025A marked increase in debt over a short period erodes financial flexibility and raises interest and refinancing risk. The rise in leverage has not improved returns (ROE fell from ~10.8% to ~9.3%), suggesting incremental debt has not yet enhanced shareholder value and may constrain strategy.
Margin SofteningA decline in net margin reduces earnings quality and resilience to cost or pricing shocks. Given the business' exposure to botanical raw material and manufacturing efficiency (company disclosures), margin erosion could indicate pressure from input costs or reimbursement changes, weakening sustainable profitability.
Tsumura & Co News
4540 FAQ
What was Tsumura & Co.’s price range in the past 12 months?
Tsumura & Co. lowest stock price was ¥3306.00 and its highest was ¥4403.00 in the past 12 months.
What is Tsumura & Co.’s market cap?
Tsumura & Co.’s market cap is ¥282.47B.
When is Tsumura & Co.’s upcoming earnings report date?
Tsumura & Co.’s upcoming earnings report date is May 13, 2026 which is in 13 days.
How were Tsumura & Co.’s earnings last quarter?
Tsumura & Co. released its earnings results on Feb 06, 2026. The company reported ¥142.95 earnings per share for the quarter, beating the consensus estimate of ¥90.935 by ¥52.015.
Is Tsumura & Co. overvalued?
According to Wall Street analysts Tsumura & Co.’s price is currently Overvalued.
Does Tsumura & Co. pay dividends?
Tsumura & Co. pays a Semiannually dividend of ¥76 which represents an annual dividend yield of 3.3%. See more information on Tsumura & Co. dividends here
What is Tsumura & Co.’s EPS estimate?
Tsumura & Co.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsumura & Co. have?
Tsumura & Co. has 76,758,360 shares outstanding.
What happened to Tsumura & Co.’s price movement after its last earnings report?
Tsumura & Co. reported an EPS of ¥142.95 in its last earnings report, beating expectations of ¥90.935. Following the earnings report the stock price went up 1.353%.
Which hedge fund is a major shareholder of Tsumura & Co.?
Currently, no hedge funds are holding shares in JP:4540
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsumura & Co.
Tsumura & Co. (4540) is a leading Japanese pharmaceutical company specializing in traditional herbal medicine, also known as Kampo medicine. Established in 1893, the company develops, manufactures, and sells a wide range of Kampo products, which are derived from natural herbal ingredients. Tsumura operates primarily in the healthcare sector, focusing on providing effective and safe therapeutic solutions that align with Japan's rich history of herbal medicine. In addition to Kampo formulations, the company is involved in research and development of new pharmaceuticals and operates in the field of health foods.
Technical Analysis
Hisamitsu Pharmaceutical Co
―
Kaken Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Pharma Foods International Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---